Unilever CEO Hein Schumacher to step down
Investing.com -- Unilever PLC (LON:ULVR) said on Tuesday that its Chief Executive Officer Hein Schumacher, is set to leave the company, in a surprise move.
The consumer goods giant said that Schumacher's departure will take effect on May 31 and that Fernando Fernandez, the current Chief Financial Officer, has been named his successor.
Schumacher's tenure at Unilever has been relatively brief, having taken over as CEO from Alan Jope in July 2023. Despite Schumacher's departure, Unilever has stated that its guidance for 2025 remains unchanged.
Fernandez brings considerable experience to his new role. Prior to serving as the company's Chief Financial Officer, he was the president of Unilever's beauty and wellbeing unit.
'The Board has been impressed with Fernando's decisive and results-oriented approach and his ability to drive change at speed. He partnered in the development of the GAP and in driving the productivity programme." Unilever Chairman Ian Meakins said in a press release.
"He has a strong track record of performance and portfolio management, a love of brands and a profound knowledge of Unilever's operations," he added.
The company also added that Fernando will receive fixed pay of Euro 1,800,000 and will be eligible to participate in an annual bonus and Performance Share Plan awards, in line with Unilever's policy.
An internal and external search process has been initiated to appoint a permanent CFO, while Srinivas Phatak, currently Unilever's Deputy CFO will serve as acting CFO.
Related Articles
Unilever CEO Hein Schumacher to step down
Tesla updates autopilot software in China, owners say move falls short of hopes
India's Reliance touts 'brain mapping' to lure IPL advertisers after Disney merger
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon's Board of Directors
CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Neurodon Corp., a leader in the development of endoplasmic reticulum (ER) stress-targeted therapeutics for diabetes and neurodegeneration, welcomes Frederick Beddingfield, III, M.D., Ph.D., a 22-year veteran of the biopharma industry, to its Board of Directors. Dr. Beddingfield is currently CEO and Board Director of Rubedo Life Sciences and has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, obesity, and other therapeutic areas. Previously, he was an Executive Partner at Apollo Health Ventures and CEO of Kira Pharmaceuticals. In 2016 he founded Sienna Biopharmaceuticals, Inc., served as President, CEO, and member of the Board, and took the company public 18 months after founding. He also served as Chief Medical Officer of Kythera Biopharmaceuticals which was acquired by Allergan for $2.1B. Dr. Beddingfield worked at Allergan for 10 years in various roles, including Therapeutic Area Head of Dermatology and Chief Medical Officer of Allergan Medical. He completed his M.D. with honors at UNC Chapel Hill, residency and fellowship training at UCLA, and a Ph.D. in Policy Analysis Research at RAND. Dr. Beddingfield is expected to contribute to Neurodon's Board in several key areas as the company transitions its pipeline to clinical development. His extensive experience developing successful products and leading companies are well-suited to facilitate the company's growth. Dr. Beddingfield stated, 'Neurodon is one of the most exciting biotech companies I have seen, and their ER-stress small molecule pipeline has great potential in metabolic diseases, sarcopenia, and neurodegeneration. I look forward to working closely with them to move the company forward and progress the pipeline.' 'Frederick's extensive experience in biotech leadership, fundraising, and commercialization will prove to be an invaluable resource as we progress our small molecules towards clinical trials. We are very excited to work with him and welcome his contributions to the Board at this critical period of our company's growth,' commented Russell Dahl, Ph.D., Neurodon's President and CEO. About Neurodon Neurodon is a preclinical company developing a first-in-class diabetes drug, NRDN-101, which is a disease-modifying, oral small molecule that is an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). SERCA dysfunction is a validated pathological driver of both Type 1 and Type 2 diabetes, and NRDN-101 reverses diabetes pathology with no observed adverse effects. Neurodon is also developing their proprietary compounds for neurodegenerative and rare diseases. For more information, visit Contactinfo@
Yahoo
2 hours ago
- Yahoo
SRx Health Solutions Announces Management and Board Changes
TAMPA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the 'Company'), a leading global health and wellness company, today announced the following management team and Board of Directors changes. Lionel Conacher, current Board member, has been appointed as Chairman of the Board, Adesh Vora, current Executive Chairman, will remain on Board and be appointed Chief Executive Officer, Kent Cunningham, current Chief Executive Officer, will assume role as President, and Nina Martinez has been appointed Chief Financial Officer. Adesh Vora, Chief Executive Officer of SRx Health Solutions, stated, 'We are grateful to our Board and senior management for their efforts in strengthening our team structure and enhancing corporate governance. These improvements align with our renewed vision for SRx Health's long-term strategic growth. Looking ahead, our core focus will be on supporting patients managing chronic and rare diseases, infusion services, clinical trials, and patient support programs to make healthcare simpler for our customers. At the same time, we will continue to build on our values—partnering with patients, pharmaceutical manufacturers, and prescriber relations.' About SRx Health Solutions, Inc. SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians. For more information on SRx Health Solutions Inc., please visit Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company's risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact:SRx Health Solutions, A. Vora, Chief Executive Officer Investor Contact:KCSA Strategic CommunicationsValter Pinto, Managing DirectorT: 212-896-1254Valter@
